Cardlytics Q3 Revenue Falls 30% to $32.9M; Q4 Guidance Signals Further Decline
CDLX sits 39% above its 52-week low of $1.57.
Summary
Cardlytics reported Q3 revenue of $32.9 million, down 30% year-over-year, with Adjusted EBITDA of just $0.4 million and negative operating cash flow of $5.9 million. Q4 guidance of $35-$39 million revenue implies the decline continues.
Key Events · Earnings and Guidance · CDLX
-
Q3 Revenue Down 30% to $32.9M
Revenue fell to $32.9 million from $47.0 million a year ago, and billings dropped 32% to $57.2 million from $84.1 million. CEO Amit Gupta said results came in below expectations.
-
Adjusted EBITDA Collapses to $0.4M
Adjusted EBITDA was $0.4 million versus $3.3 million a year ago, an 88% decline. Net loss narrowed to $(8.9) million from $(72.7) million, though that prior figure included a $58.8 million goodwill impairment.
-
Cash Burn and Leverage Stack Up
Operating cash flow was $(5.9) million versus $1.8 million provided a year ago, and free cash flow was $(1.6) million. Cash stood at $29.9 million against $169.7 million of convertible notes and $25.0 million drawn on credit lines.
-
Q4 Guidance Still Declining
Q4 2026 guidance: billings $63.0-$69.0 million (down 22-29%), revenue $35.0-$39.0 million (down 23-31%), Adjusted Contribution $20.0-$23.0 million, Adjusted EBITDA $(1.0)-$2.0 million.
Analysis · CDLX · Technology
The top line fell 30% year-over-year to $32.9 million and billings dropped 32%, with management acknowledging results came in below expectations. Profitability on an adjusted basis is now razor-thin: Adjusted EBITDA was just $0.4 million, down from $3.3 million, and operations consumed $5.9 million of cash in the quarter. That leaves $29.9 million of cash against $169.7 million of convertible notes and $25.0 million drawn on credit lines. Guidance for Q4 points to revenue of $35-$39 million, still down 23-31% year-over-year, so the decline has not bottomed. Margin is the lone bright spot: Adjusted Contribution was 33.9% of billings versus 30.4% a year ago, reflecting the leaner cost base after the Bridg divestiture.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDLX was trading at $2.19 on NASDAQ in the Technology sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $1.57 to $18.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.